# Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD

> **NCT02515838** · PHASE2 · COMPLETED · sponsor: **Modus Therapeutics AB** · enrollment: 147 (actual)

## Conditions studied

- Sickle-Cell Disease

## Interventions

- **DRUG:** Sevuparin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02515838
- **Lead sponsor:** Modus Therapeutics AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2019-05
- **Final completion:** 2019-05
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2019-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02515838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02515838, "Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02515838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*